ESR2 and endometrial cancer: In different groups of endometrial cancer cell lines, the expression of ERβ and p53 in the cells treated with formononetin was significantly increased, as expected (all P < 0.05 relative to the control group); In addition, the higher the concentration of formononetin, the more the expression of ERβ and p53 (all P < 0.05 relative to the 40 μM group; Figs. 9A and 9B).